Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Altria Holds 2022 Annual Meeting of Shareholders; Reaffirms 2022 Full-Year Earnings Guidance; Declares Regular Quarterly Dividend of $0.90 Per Share

Altria Group, Inc. (NYSE: MO) held its 2022 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria’s Chief Executive Officer, summarized our full-year 2021 and first-quarter 2022 financial results and discussed our progress toward our Vision and Environmental, Social and Governance (ESG) goals. Mr. Gifford also reaffirmed our guidance for adjusted diluted earnings per share (EPS) and addressed shareholder questions. Copies of these prepared remarks and business presentation and a replay of the audio webcast of the Annual Meeting are available on www.altria.com.

Preliminary Voting Results for Altria’s Annual Meeting

The preliminary voting results at the Annual Meeting were as follows: our shareholders elected to a one-year term each of the 12 nominees for our Board of Directors (Board) named in our proxy statement, ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2022, approved, on an advisory basis, the compensation of our named executive officers and approved one shareholder proposal. Final voting results will be reported in a Current Report on Form 8-K that we will file with the U.S. Securities and Exchange Commission.

2022 Full-Year Guidance

In the remarks, Mr. Gifford reaffirmed our guidance to deliver 2022 full-year adjusted diluted EPS in a range of $4.79 to $4.93, representing a growth rate of 4% to 7% from an adjusted diluted EPS base of $4.61 in 2021, as shown in Schedule 1. This guidance range excludes the special items for the first quarter of 2022 shown in Schedule 1. We continue to expect that 2022 adjusted diluted EPS growth will be weighted toward the second half of the year. While the 2022 full-year adjusted diluted EPS guidance accounts for a range of scenarios, the external environment remains dynamic. We will continue to monitor conditions related to (i) the economy, including the impact of increased inflation and global supply chain disruptions, (ii) the impact of current and future COVID-19 variants and mitigation strategies, (iii) adult tobacco consumer dynamics, including tobacco usage occasions, available disposable income, purchasing patterns and adoption of smoke-free products, (iv) regulatory and legislative developments and (v) the impacts of the Russian invasion of Ukraine.

Our 2022 full-year adjusted diluted EPS guidance range includes planned investments in support of our Vision, such as (i) enhancement of our digital consumer engagement system, (ii) increased smoke-free product research, development and regulatory preparation expenses and (iii) marketplace activities in support of our smoke-free products. The guidance range also includes anticipated inflationary increases in Master Settlement Agreement (MSA) expenses, direct materials costs and our current expectation that PM USA will not have access to the IQOS system in 2022.

Our full-year adjusted diluted EPS guidance range excludes the impact of certain income and expense items that management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition-related and disposition-related costs, equity investment-related special items (including any changes in fair value of our equity investment recorded using the fair value option and any changes in the fair value of related warrants and preemptive rights), certain income tax items, charges associated with tobacco and health and certain other litigation items, and resolutions of certain non-participating manufacturer (NPM) adjustment disputes under the MSA (such dispute resolutions are referred to as NPM Adjustment Items).

Our management cannot estimate on a forward-looking basis the impact of certain income and expense items, including those items noted in the preceding paragraph, on our reported diluted EPS because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, we do not provide a corresponding U.S. generally accepted accounting principles (GAAP) measure for, or reconciliation to, our adjusted diluted EPS guidance.

Regular Quarterly Dividend

Following the Annual Meeting, our Board declared a regular quarterly dividend of $0.90 per share, payable on July 11, 2022, to shareholders of record as of June 15, 2022. The ex-dividend date is June 14, 2022. Future dividend payments remain subject to the discretion of our Board.

Altria’s Profile

We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. Our Vision by 2030 is to responsibly lead the transition of adult smokers to a smoke-free future (Vision). We are Moving Beyond Smoking™, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices - believing it is a substantial opportunity for adult tobacco consumers, our businesses and society.

Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, and Helix Innovations LLC (Helix), a rapidly growing manufacturer of oral nicotine pouches. We also enhance our smoke-free product portfolio with exclusive U.S. commercialization rights to the IQOS Tobacco Heating System® and Marlboro HeatSticks®, and an equity investment in JUUL Labs, Inc. (JUUL).

We also own equity investments in Anheuser-Busch InBev SA/NV (ABI), the world’s largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

The brand portfolios of our tobacco operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal® and on!®. Trademarks and service marks related to Altria referenced in this release are the property of Altria or its subsidiaries or are used with permission.

Learn more about Altria at www.altria.com and follow us on Twitter, Facebook and LinkedIn.

Forward Looking and Cautionary Statements

This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Important factors that may cause actual results to differ from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and our most recent Annual Report on Form 10-K for the year ended December 31, 2021. These factors include the following:

  • unfavorable litigation outcomes, including risks associated with adverse jury and judicial determinations, courts and arbitrators reaching conclusions at variance with our or any of our investees’ understanding of applicable law, bonding requirements in the jurisdictions that do not limit the dollar amount of appeal bonds, and certain challenges to bond cap statutes;
  • government (including the U.S. Food and Drug Administration (FDA)) and private sector actions that impact adult tobacco consumer acceptability of, or access to, tobacco products;
  • tobacco product taxation, including lower tobacco product consumption levels and potential shifts in adult tobacco consumer purchases as a result of federal, state and local excise tax increases, and excise taxes on e-vapor and oral nicotine products and the impact on adult tobacco consumers’ transition to lower priced tobacco products;
  • unfavorable outcomes of any government investigations of us or our investees;
  • a successful challenge to our tax positions, an increase to the corporate income tax rate or other changes to federal or state tax laws;
  • the risks related to our and our investees’ international business operations, including failure to prevent violations of various United States and foreign laws and regulations such as foreign privacy laws and laws prohibiting bribery and corruption;
  • the risks associated with health epidemics and pandemics, including the COVID-19 pandemic and similar outbreaks, such as their impact on our and our investees’ ability to continue manufacturing and distributing products (directly or indirectly due to their impact on suppliers, distributors and distribution chain service providers) and their impact on macroeconomic conditions and, in turn, adult tobacco consumer purchasing behavior;
  • the failure of our and our investees’ efforts to compete effectively in their respective markets;
  • the growth of the e-vapor category and other innovative tobacco products, including oral nicotine pouches, contributing to reductions in cigarette and MST consumption levels and sales volume;
  • our ability to promote brand equity successfully; anticipate and respond to evolving adult tobacco consumer preferences; develop, manufacture, market and distribute products that appeal to adult tobacco consumers; promote productivity; and protect or enhance margins through cost savings and price increases;
  • our unsuccessful commercialization of innovative products or processes, including innovative tobacco products that may reduce the health risks associated with cigarettes and other traditional tobacco products, and that appeal to adult tobacco consumers;
  • changes, including in macroeconomic and geopolitical conditions (including inflation), that result in shifts in adult tobacco consumer disposable income and purchasing behavior, including choosing lower-priced and discount brands;
  • significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, climate and geopolitical conditions, including the Russian invasion of Ukraine;
  • the risks, including FDA regulatory risks, related to our and our investees’ reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers, and the risk of an extended disruption at a facility of, or of service by, a supplier, distributor or distribution chain service provider of our tobacco subsidiaries or our investees;
  • required or voluntary product recalls as a result of various circumstances such as product contamination or FDA or other regulatory action;
  • the failure of our information systems or the information systems of key suppliers or service providers to function as intended, or cyber attacks or security breaches;
  • our inability to attract and retain the best talent due to the impact of decreasing social acceptance of tobacco usage, tobacco control actions and other factors, including current labor market dynamics;
  • impairment losses as a result of the write down of intangible assets, including goodwill;
  • the adverse effect of acquisitions, investments, dispositions or other events on our credit rating;
  • our inability to acquire attractive businesses or make attractive investments on favorable terms, or at all, or to realize the anticipated benefits from an acquisition or investment and our inability to dispose of businesses or investments on favorable terms or at all;
  • the risks related to disruption and uncertainty in the credit and capital markets, including risk of access to these markets both generally and at current prevailing rates, which may adversely affect our earnings or dividend rate or both;our inability to attract and retain investors due to the impact of decreasing social acceptance of tobacco usage or unfavorable ESG ratings;
  • the risk that any challenge to our investment in JUUL, if successful, could result in a broad range of resolutions, including divestiture of the investment or rescission of the transaction;
  • the risks generally related to our investments in JUUL and Cronos, including our inability to realize the expected benefits of our investments in the expected time frames, or at all, due to the risks encountered by our investees in their businesses, such as operational, competitive, compliance, litigation and reputational risks, and legislative and regulatory risks at the international, federal, state and local levels; and impairment of our investment in Cronos and changes in the fair value of our investment in JUUL;
  • the risks related to our inability to acquire a controlling interest in JUUL as a result of standstill restrictions or to control the material decisions of JUUL, restrictions on our ability to sell or otherwise transfer our shares of JUUL until December 20, 2024, and non-competition restrictions for the same time period subject to certain exceptions;
  • the risks associated with our investment in ABI, including effects of the COVID-19 pandemic, foreign currency exchange rates and macroeconomic and geopolitical conditions, including the Russian invasion of Ukraine, on ABI’s business and the impact on our earnings from, and carrying value of, our investment in ABI;
  • the risks related to our ownership percentage in ABI decreasing below certain levels, including additional tax liabilities, a reduction in the number of directors that we have the right to have appointed to the ABI board of directors and our potential inability to use the equity method of accounting for our investment in ABI;
  • the risk of challenges to the tax treatment of the consideration we received in the ABI/SABMiller plc business combination and the tax treatment of our equity investment; and
  • the risks, including criminal, civil or tax liability, related to our or Cronos’s failure to comply with applicable laws, including cannabis laws.

We caution that the foregoing list of factors is not complete and we do not undertake to update any forward-looking statements that we may make except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

Schedule 1

ALTRIA GROUP, INC.

and Subsidiaries

Reconciliation of GAAP and non-GAAP Measures

(dollars in millions, except per share data)

(Unaudited)

 

 

 

 

 

 

Reconciliation of Altria’s Full Year 2021 Adjusted Results

 

Earnings

before

Income

Taxes

Provision for

Income

Taxes

Net

Earnings

Net

Earnings

Attributable

to Altria

Diluted

EPS

2021 Reported

$

3,824

 

$

1,349

 

$

2,475

 

$

2,475

 

$

1.34

 

NPM Adjustment Items

 

(76

)

 

(19

)

 

(57

)

 

(57

)

 

(0.03

)

Asset impairment, exit, implementation, acquisition and disposition-related costs

 

120

 

 

21

 

 

99

 

 

99

 

 

0.05

 

Tobacco and health and certain other

litigation items

 

182

 

 

44

 

 

138

 

 

138

 

 

0.07

 

ABI-related special items

 

6,203

 

 

1,302

 

 

4,901

 

 

4,901

 

 

2.66

 

Cronos-related special items

 

466

 

 

(4

)

 

470

 

 

470

 

 

0.25

 

Loss on early extinguishment of debt

 

649

 

 

153

 

 

496

 

 

496

 

 

0.27

 

Income tax items

 

 

 

3

 

 

(3

)

 

(3

)

 

 

2021 Adjusted for Special Items

$

11,368

 

$

2,849

 

$

8,519

 

$

8,519

 

$

4.61

 

Reconciliation of Altria’s First Quarter 2022 Adjusted Results

 

Earnings

before

Income

Taxes

Provision for

Income

Taxes

Net

Earnings

Net

Earnings

Attributable

to Altria

Diluted

EPS

2022 Reported

$

2,673

 

$

714

 

$

1,959

 

$

1,959

 

$

1.08

 

NPM Adjustment Items

 

(60

)

 

(15

)

 

(45

)

 

(45

)

 

(0.02

)

Asset impairment, exit, implementation, acquisition and disposition-related costs

 

7

 

 

2

 

 

5

 

 

5

 

 

 

Tobacco and health and certain other

litigation items

 

12

 

 

3

 

 

9

 

 

9

 

 

 

JUUL changes in fair value

 

100

 

 

 

 

100

 

 

100

 

 

0.05

 

ABI-related special items

 

(59

)

 

(12

)

 

(47

)

 

(47

)

 

(0.02

)

Cronos-related special items

 

61

 

 

 

 

61

 

 

61

 

 

0.03

 

Income tax items

 

 

 

(5

)

 

5

 

 

5

 

 

 

2022 Adjusted for Special Items

$

2,734

 

$

687

 

$

2,047

 

$

2,047

 

$

1.12

 

While we report our financial results in accordance with GAAP, our management reviews certain financial results, including diluted EPS, on an adjusted basis, which excludes certain income and expense items, including those items noted under “2022 Full-Year Guidance.” Our management does not view any of these special items to be part of our underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Our management believes that adjusted financial measures provide useful additional insight into underlying business trends and results and provide a more meaningful comparison of year-over-year results. Our management uses adjusted financial measures for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with, GAAP and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.

Contacts

Altria Client Services

Investor Relations

804-484-8222

Altria Client Services

Media Relations

804-484-8897

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.